The Incretin Effect and Secretion in Obese and Lean Women with Polycystic Ovary Syndrome: A Pilot Study
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Insulin resistance is considered to play an important role in the pathogenesis of polycystic ovary syndrome (PCOS) and in the progression to type 2 diabetes. Recent reports concentrate on a possible relationship between incretin secretion and beta-cell function in PCOS. The aim of the present study is to investigate the incretin effect in obese and lean women with PCOS. METHODS: Twenty women with PCOS and ten age-matched healthy women were recruited in the study. The oral glucose tolerance test (OGTT) and isoglycemic test were carried out on each participant after an overnight fast at 2-weeks interval. Plasma levels of insulin, glucose, C-peptide, glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) were assayed. RESULTS: Obese women with PCOS demonstrated lower GIP concentrations (area under the curve [AUC]) in response to OGTT compared to the control group. The incretin effect was found significantly augmented in the obese women with PCOS compared to controls. This finding remained robust in the subgroup analysis including only body mass index (BMI)-matched healthy women. CONCLUSIONS: Increased insulinotropic effect could counteract the blunted GIP response to OGTT in obese women with PCOS. It is suggested that the pathology of PCOS may also include impaired activity of the enteroinsular axis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Katz, A., Nambi, S. S., Mather, K., Baron, A. D., Follmann, D. A., Sullivan, G., & Quon, M. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.7.6661 · Cited by 3,931 · cited 1×
“The assays have 100% cross-reactivity to the intact forms of human GIP (1-42) and GLP-1 (7-36) and the inactive forms GIP (3-42) and GLP-1 (9-36) after N-terminal cleavage by the enzyme dipeptidyl peptidase-4 (DPP-4).”
Legro, R. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.1.165 · Cited by 1,743
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · cited 1×
“The assays have 100% cross-reactivity to the intact forms of human GIP (1-42) and GLP-1 (7-36) and the inactive forms GIP (3-42) and GLP-1 (9-36) after N-terminal cleavage by the enzyme dipeptidyl peptidase-4 (DPP-4).”
Muscelli, E., Mari, A., Casolaro, A., Camastra, S., Seghieri, G., Gastaldelli, A., Holst, J. J., & Ferrannini, E. (2008) · Diabetes · doi:10.2337/db07-1315 · Cited by 409 · cited 1×
“The assays have 100% cross-reactivity to the intact forms of human GIP (1-42) and GLP-1 (7-36) and the inactive forms GIP (3-42) and GLP-1 (9-36) after N-terminal cleavage by the enzyme dipeptidyl peptidase-4 (DPP-4).”
Elahi, D., Andersen, D. K., Muller, D. C., Tobin, J. D., Brown, J. C., & Andres, R. (1984) · Diabetes · doi:10.2337/diab.33.10.950 · Cited by 87 · cited 1×
“The assays have 100% cross-reactivity to the intact forms of human GIP (1-42) and GLP-1 (7-36) and the inactive forms GIP (3-42) and GLP-1 (9-36) after N-terminal cleavage by the enzyme dipeptidyl peptidase-4 (DPP-4).”
Incretin levels in polycystic ovary syndrome
Vrbikova, J., Hill, M., Bendlova, B., Grimmichova, T., Dvorakova, K., Vondra, K., & Pacini, G. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0097 · Cited by 81 · cited 1×
“The assays have 100% cross-reactivity to the intact forms of human GIP (1-42) and GLP-1 (7-36) and the inactive forms GIP (3-42) and GLP-1 (9-36) after N-terminal cleavage by the enzyme dipeptidyl peptidase-4 (DPP-4).”
Cited by
Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists
Gasbjerg, L. S., Bergmann, N. C., Stensen, S., Christensen, M. B., Rosenkilde, M. M., Holst, J. J., Nauck, M., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170183 · Cited by 121
Outeiriño-Iglesias, V., Romaní-Pérez, M., González-Matías, L. C., Vigo, E., & Mallo, F. (2015) · Endocrinology · doi:10.1210/en.2014-1978 · Cited by 99
Jensterle, M., Kocjan, T., Kravos, N. A., Pfeifer, M., & Janez, A. (2015) · Endocrine Research · doi:10.3109/07435800.2014.966385 · Cited by 86
“reports on the impaired secretion of endogenous GLP-1 in PCOS patients (23,24).”
BackgroundJensterle, M., Herman, R., & Janež, A. (2022) · Biomedicines · doi:10.3390/biomedicines10081989 · Cited by 50
Nishiyama, Y., Hasegawa, T., Fujita, S., Iwata, N., Nagao, S., Hosoya, T., Inagaki, K., Wada, J., & Otsuka, F. (2018) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2017.11.004 · Cited by 43
Metadata
- Authors
- Pontikis, C., Yavropoulou, M. P., Toulis, K. A., Kotsa, K., Kazakos, K., Papazisi, A., Gotzamani-Psarakou, A., & Yovos, J. G.
- Venue
- Journal of Women's Health
- Publisher
- SAGE Publications
- Published
- 2011-06
- Volume
- 20
- Issue
- 6
- Pages
- 971-976
- ISSN
- 1059-7115 (ISSN-L)
- 1540-9996
- 1931-843X
- OpenAlex
- W2047490259
- Cited by
- 41
- References
- 6
- FWCI
- 2.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Incretin Effect and Secretion in Obese and Lean Women with Polycystic Ovary Syndrome: A Pilot Study. https://app.cochat.ai/papers/10.1089/jwh.2010.2272
- The paper
- Pontikis, C., Yavropoulou, M. P., Toulis, K. A., Kotsa, K., Kazakos, K., Papazisi, A., Gotzamani-Psarakou, A., & Yovos, J. G. (2011). The Incretin Effect and Secretion in Obese and Lean Women with Polycystic Ovary Syndrome: A Pilot Study. Journal of Women's Health. https://doi.org/10.1089/jwh.2010.2272
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.